New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 27, 2011
14:07 EDTMRKEarnings Preview: Merck trading up ahead of Q3 earnings
Merck (MRK) is expected to report Q3 earnings before the market open on Friday, October 28 with a conference call scheduled for 8:00 am ET. Analysts are looking for EPS of 91c on revenue of $11.61B. The consensus range is 83c-93c for EPS, and $11.47B-$11.95B for revenue, according to First Call. In Q2, Merck reported in-line EPS and better-than-expected revenue. It also reported sales growth for Singular, Remicade, and Animal Health, while raising the full-year EPS to $3.68-$3.76. In its previous conference call, the company announced plans to reduce the workforce by 12%-13% by 2015. The measure would save the company $3.5B by the end of FY12. To accelerate the goal, the Associated Press reported the company may speed up the layoffs to reach that goal. In the previous quarter, Merck announced positive clinical results for several drugs: Isentress, Delura, Odanacatib, and Gardasil. In fact, the CDC voted to expand the use of Gardasil. Investors will also look for updates on the progress of its new type 2 diabetes treatment Juvisync, which recently received FDA approval. Meanwhile, the company signed various research and colloboration agreements with AbD Serotec, Serum Institute of India, and BGI. The company may also mention its sale of its 50% interest in the Johnson & Johnson-Merck joint venture for $175M. Merck was upgraded to Buy at Jeffries, citing valuation and capital allocation. Barron's also said Merck was attractive for its dividend yield, restructuring savings, and expansion in emerging markets.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use